Baseline clinical features in the studies included in the meta-analysis
| Study | Age (year, SD) | Male (%) | DM (%) | CKD (%) | AF (%) | CAD (%) | COPD (%) | |||||||
| FMR | DMR | FMR | DMR | FMR | DMR | FMR | DMR | FMR | DMR | FMR | DMR | FMR | DMR | |
| ACCESS-EU | 73 (9) | 75.6 (12) | 267 | 59 | 134 | 17 | 189 | 30 | 248 | 67 | 267 | 48 | 79 | 17 |
| Braun et al. 201414 | 70.7 (10) | 72.2 (12) | 36 | 44 | 9 | 7 | 24 | 14 | 33 | 36 | 33 | 30 | 12 | 11 |
| Chan et al. 201216 | 71 (14) | 77 (10) | 9 | 8 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EVEREST II HRR | N/A | N/A | 91 | 37 | 66 | 19 | 48 | 17 | 92 | 42 | N/A | N/A | N/A | N/A |
| EVEREST II RCT | 68 | 67 | 23 | 90 | 7 | 7 | 4 | 3 | 21 | 39 | 35 | 48 | 15 | 12 |
| EVEREST II REALISM | 74 (11) | 73 (9) | 272 | 106 | 180 | 47 | 136 | 51 | 303 | 140 | 369 | 121 | 145 | 59 |
| GRASP | 72 (11) | 73 (9) | 59 | 19 | 35 | 5 | 36 | 8 | 36 | 11 | 50 | 7 | 21 | 3 |
| Pilot European sentinel registry | 72.8 (10) | 78.3 (8) | 306 | 75 | 150 | 18 | 148 | 35 | 123 | 72 | 144 | 37 | 90 | 29 |
| Rudolph et al. 201319 | 73 (9) | 77 (9) | 109 | 39 | 57 | 18 | 96 | 29 | 93 | 53 | 111 | 41 | 35 | 12 |
| Pooled population | 73.1 (10) | 78.1 (10) | 1172(66) | 477(57) | 638(36) | 138(23) | 681(39) | 187(23) | 949 (54) | 460(56) | 1009(62) | 332(44) | 397(25) | 143(19) |
| p Value | <0.001 | <0.001 | <0.001 | <0.001 | 0.214 | <0.001 | 0.003 | |||||||
AF, atrial fibrillation; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; DMR, degenerative mitral regurgitation; EVEREST II, Endovascular Valve Edge-to-Edge Repair Study II; FMR, functional mitral regurgitation; RCT, randomised controlled trial.